Cargando…

Baseline Prognostic Factors and Statistic Model to Predict Early Virological Response in Telbivudine-Treated Patients With Chronic Hepatitis B

BACKGROUND: Hepatitis B virus (HBV) infection is still a worldwide disease, which may cause liver cirrhosis or even hepatocellular carcinoma. Telbivudine is a potent nucleoside analogue used in the treatment of chronic hepatitis B (CHB); however, drug resistance has remained a challenge. As early vi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Rui, Zhou, Yuan-Ping, Lin, Chun, Gao, Hai-bing, Huang, Shui-wen, Huang, Zu-xiong, Sun, Fang, Lin, Yong, Zhang, Dong-qing, Lin, Qing-feng, Ao, Wen, Pan, Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kowsar 2013
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3877653/ https://www.ncbi.nlm.nih.gov/pubmed/24403918 http://dx.doi.org/10.5812/hepatmon.15573

Ejemplares similares

Composition and Interactions of Hepatitis B Virus Quasispecies Defined the Virological Response During Telbivudine Therapy
por: Zhou, Bin, et al.
Publicado: (2015)

Effects of Telbivudine Treatment on the Circulating CD4(+) T-Cell Subpopulations in Chronic Hepatitis B Patients
por: Zheng, Yanhua, et al.
Publicado: (2012)

Short Term Virologic Efficacies of Telbivudine versus Entecavir against Hepatitis B-Related Hepatocellular Carcinoma
por: Kim, Young Woon, et al.
Publicado: (2015)

Case report: lactic acidosis and rhabdomyolysis during telbivudine and tenofovir treatment for chronic hepatitis B
por: Ying, Yue, et al.
Publicado: (2018)

Efficacy of telbivudine with conditional tenofovir intensification in patients with chronic hepatitis B: results from the 2-year roadmap strategy
por: Piratvisuth, Teerha, et al.
Publicado: (2016)

Telbivudine can safely reduce mother-to-child transmission in chronic hepatitis B women after 12 weeks of gestation
por: Han, Li-fen, et al.
Publicado: (2019)

Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance
por: Wang, Guiliang, et al.
Publicado: (2015)

Safety and efficacy of telbivudine for the treatment of chronic hepatitis B
por: Osborn, Melissa K
Publicado: (2009)

Telbivudine treatment of hepatitis B virus-infected pregnant women at different gestational stages for the prevention of mother-to-child transmission: Outcomes of telbivudine treatment during pregnancy
por: Tan, Zhangmin, et al.
Publicado: (2016)

Efficacy and safety of telbivudine treatment for the prevention of HBV perinatal transmission
por: Ren, Cuicui, et al.
Publicado: (2020)

Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B
por: Hou, Jin-Lin, et al.
Publicado: (2015)

Telbivudine and adefovir combination therapy for patients with chronic lamivudine-resistant hepatitis B virus infections
por: Lin, Ming-Tsung, et al.
Publicado: (2013)

Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic review
por: Zhao, Shushan, et al.
Publicado: (2010)

The effects of telbivudine in late pregnancy to prevent intrauterine transmission of the hepatitis B virus: a systematic review and meta-analysis
por: Deng, Min, et al.
Publicado: (2012)

Dynamic analysis of CD127 expression on memory CD8 T cells from patients with chronic hepatitis B during telbivudine treatment
por: Lv, Guocai, et al.
Publicado: (2010)

Two cases of telbivudine-induced myopathy in siblings with chronic hepatitis B
por: Kim, Eun Hye, et al.
Publicado: (2013)

Effectiveness of entecavir or telbivudine therapy in patients with chronic hepatitis B virus infection pre-treated with interferon compared with de novo therapy with entecavir and telbivudine
por: Cai, Shaohang, et al.
Publicado: (2017)

Motor development delay in offspring is associated with prenatal telbivudine exposure
por: Zhou, Chengliang, et al.
Publicado: (2018)

Durability of Telbivudine-Associated Improvement of Renal Function Following Withdrawal or Switching of Antivirals in Chronic Hepatitis B Patients
por: Hsu, Chao-Wei, et al.
Publicado: (2017)

Clinicopathological Features of Telbivudine-Associated Myopathy
por: Ambang, Tomica, et al.
Publicado: (2016)

Telbivudine treatment started in early and middle pregnancy completely blocks HBV vertical transmission
por: Sun, Weihui, et al.
Publicado: (2017)

Factors Related to Significant Improvement of Estimated Glomerular Filtration Rates in Chronic Hepatitis B Patients Receiving Telbivudine Therapy
por: Lin, Te-Fu, et al.
Publicado: (2017)

Hepatitis B virus genotype is an independent prognostic factor of telbivudine and tenofovir treatment in hepatitis B surface antigen‐positive pregnant women
por: Zhang, Baofang, et al.
Publicado: (2021)

Infant immune response to hepatitis B vaccine after fetal exposure to telbivudine
por: Li, Yandi, et al.
Publicado: (2022)

Telbivudine-Induced Myopathy: Clinical Features, Histopathological Characteristics, and Risk Factors
por: Lan, Min-Yu, et al.
Publicado: (2023)

Baseline High Viral Load and Unfavorable Patterns of Alanine Aminotransferase Change Predict Virological Relapse in Patients With Chronic Hepatitis C Genotype 1 or 2 Obtaining Rapid Virological Response During Antiviral Therapy
por: Lin, Kung-Hung, et al.
Publicado: (2013)

Kinetics of hepatitis B surface antigen and estimated glomerular filtration rate in telbivudine-treated hepatitis B patients with different rescue strategies
por: Yu, Hsien-Chung, et al.
Publicado: (2020)

Pegylated interferon/telbivudine sequential therapy in Hepatitis Be antigen negative severe chronic hepatitis B patient
por: Caroleo, Benedetto, et al.
Publicado: (2013)

Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B
por: Wang, Y, et al.
Publicado: (2013)

Efficacy of telbivudine on interruption of hepatitis B virus vertical transmission: a meta-analysis
por: Liu, Min-Hui, et al.
Publicado: (2013)

Role of tenofovir and telbivudine in treatment of hepatitis B related acute on chronic liver failure
por: Malakar, Debraj, et al.
Publicado: (2021)

Myotoxicity of telbivudine in pre-existing muscle damage
por: Finsterer, Josef, et al.
Publicado: (2010)

Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections
por: Gan, Weiqiang, et al.
Publicado: (2020)

Effect and Predictive Elements for 52 Weeks’ Telbivudine Treatment on Naïve HBeAg positive Chronic Hepatitis B
por: Zhu, Xiao-Feng, et al.
Publicado: (2011)

Effectiveness of telbivudine antiviral treatment in patients with hepatitis B virus-associated glomerulonephritis: A 104-week pilot study
por: Yan, Zhaoping, et al.
Publicado: (2018)

Effect of WSP, a Chinese Herbal Formula, on Th17/Treg Ratio and HBeAg Seroconversion in Telbivudine-Treated HBeAg-Positive Chronic Hepatitis B Patients with High Baseline ALT Levels (20–30 Times the ULN)
por: Zhang, Yang, et al.
Publicado: (2019)

Virological Predictors of Response to Retreatment in Hepatitis C Genotype 2 Infected Patients
por: Huang, Chung-Feng, et al.
Publicado: (2013)

Comparison of telbivudine and entecavir on the change of off- treatment eGFR after 3 years of treatment in non-cirrhotic chronic hepatitis B patients
por: Lin, Yang-Sheng, et al.
Publicado: (2017)

The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection
por: He, Linye, et al.
Publicado: (2019)

Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial
por: An, Jihyun, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ktbekefp9unc6v7caf03ab0llr